Comprehensive Access to Verified HCPs and In-Depth Data Across Asthma, COPD, IPF, and Other Key Pulmonary Conditions
Konovo’s Pulmonary Therapeutic Breakdown offers a detailed view into global market research capabilities across critical respiratory conditions, including asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis (IPF), pneumonia, sleep disorders, respiratory syncytial virus (RSV), and pulmonary arterial hypertension (PAH). With more than 315 projects completed and 18,925 respondent completes over the past three years, we leverage a panel of 2 million+ verified healthcare professionals across 150 therapeutic areas. Our unmatched reach—spanning the Americas, Canada, Europe, and Asia—ensures representative, high-quality samples supported by rigorous quality controls. By combining proprietary technologies with expert project management, Konovo delivers accurate, actionable pulmonary market insights to help pharmaceutical, biotech, and medical device companies make informed, data-driven decisions.